Cerapedics raises $19M in Series C round
Medical device company Cerapedics raises $19 million in a Series C funding round for its cervical spine bone graft technology.
Cerapedics said it closed a Series C equity round worth $19 million, led by new investors MedImmune Ventures and CVF LLC, an affiliate of Henry Crown & Co.
Existing backers OrbiMed Advisors and NGN Capital also participated, according to a press release.
Cerapedics said it plans to spend the proceeds on the investigation device exemption trial of its i-Factor peptide-enhanced bone graft technology, which is designed to treat problems in the cervical spine "and prepare for commercialization upon FDA approval," according to the release.